LTR Pharma Ltd LTP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- A$1.89
- Day Range
- A$1.77–1.93
- 52-Week Range
- A$0.24–2.11
- Bid/Ask
- A$1.80 / A$1.92
- Market Cap
- A$291.46 Mil
- Volume/Avg
- 706,804 / 966,679
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men’s health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.ltrpharma.com
Comparables
Valuation
|
Metric
|
LTP
|
009420
|
039200
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 374.30 | — |
Price/Book Value | 89.84 | 12.02 | 16.71 |
Price/Sales | — | 15.17 | 315.84 |
Price/Cash Flow | — | — | — |
Price/Earnings
LTP
009420
039200
Financial Strength
|
Metric
|
LTP
|
009420
|
039200
|
|---|---|---|---|
Quick Ratio | 18.70 | 2.00 | 2.29 |
Current Ratio | 19.23 | 3.14 | 2.37 |
Interest Coverage | — | −118.68 | −131.58 |
Quick Ratio
LTP
009420
039200
Profitability
|
Metric
|
LTP
|
009420
|
039200
|
|---|---|---|---|
Return on Assets (Normalized) | — | −1.76% | −24.13% |
Return on Equity (Normalized) | — | −2.31% | −31.91% |
Return on Invested Capital (Normalized) | — | −2.61% | −34.10% |
Return on Assets
LTP
009420
039200
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Nxgvtprvs | Vgs | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Wnhbvylh | Pgtkld | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Tbhfmyvh | Jlwmnp | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Dgjtkpy | Kzhgcr | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Rqgfgqjss | Tycs | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Xywvthz | Lfq | $29.2 Bil | |||
| Moderna Inc
MRNA
| Ygmxkkh | Bdrxs | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Tssmqnjs | Fnr | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Qpvgxwsv | Xtswll | $13.2 Bil | |||
| Incyte Corp
INCY
| Rwtvxzr | Sryky | $13.0 Bil |
United States